Futurity May 6, 2024
The implications of high prices for new diabetes and obesity therapies are alarming, according to researchers.
For years, Kasia Lipska, associate professor of medicine (endocrinology) at Yale School of Medicine (YSM), has been advocating for affordable pricing of insulin, an essential—and sometimes lifesaving—drug for many individuals with diabetes.
Now, she is turning her attention to a similar trend of soaring prices among new diabetes and obesity medications.
The implications of exorbitant prices for these therapies are alarming, according to Lipska, who first became aware of the drug pricing issue in 2016 when one of her patients couldn’t afford to increase the dose of insulin she was taking. In subsequent research, Lipska discovered that 1.1 million Americans, or 14% of those...
Today's Sponsors
Today's Sponsor